gDNA enrichment by a transposase-based technology for NGS analysis of the whole sequence of BRCA1, BRCA2, and 9 genes involved in DNA damage repair
- PMID: 25350069
- PMCID: PMC4828150
- DOI: 10.3791/51902
gDNA enrichment by a transposase-based technology for NGS analysis of the whole sequence of BRCA1, BRCA2, and 9 genes involved in DNA damage repair
Abstract
The widespread use of Next Generation Sequencing has opened up new avenues for cancer research and diagnosis. NGS will bring huge amounts of new data on cancer, and especially cancer genetics. Current knowledge and future discoveries will make it necessary to study a huge number of genes that could be involved in a genetic predisposition to cancer. In this regard, we developed a Nextera design to study 11 complete genes involved in DNA damage repair. This protocol was developed to safely study 11 genes (ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, PALB2, RAD50, RAD51C, RAD80, and TP53) from promoter to 3'-UTR in 24 patients simultaneously. This protocol, based on transposase technology and gDNA enrichment, gives a great advantage in terms of time for the genetic diagnosis thanks to sample multiplexing. This protocol can be safely used with blood gDNA.
Similar articles
-
Detection of genomic variations in BRCA1 and BRCA2 genes by long-range PCR and next-generation sequencing.J Mol Diagn. 2012 May-Jun;14(3):286-93. doi: 10.1016/j.jmoldx.2012.01.013. Epub 2012 Mar 16. J Mol Diagn. 2012. PMID: 22426013
-
Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition.Breast Cancer Res Treat. 2012 Jun;133(3):1179-90. doi: 10.1007/s10549-012-2009-5. Epub 2012 Apr 5. Breast Cancer Res Treat. 2012. PMID: 22476849
-
Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.Cancer. 2015 Jan 1;121(1):25-33. doi: 10.1002/cncr.29010. Epub 2014 Sep 3. Cancer. 2015. PMID: 25186627
-
Gene analysis techniques and susceptibility gene discovery in non-BRCA1/BRCA2 familial breast cancer.Surg Oncol. 2015 Jun;24(2):100-9. doi: 10.1016/j.suronc.2015.04.003. Epub 2015 Apr 13. Surg Oncol. 2015. PMID: 25936246 Review.
-
BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair.Carcinogenesis. 2010 Jun;31(6):961-7. doi: 10.1093/carcin/bgq069. Epub 2010 Apr 16. Carcinogenesis. 2010. PMID: 20400477 Review.
References
-
- Cornelisse CJ, Cornelis RS, Devilee P. Genes responsible for familial breast cancer. Pathol. Res. Pract. 1996;192(7):684–693. - PubMed
-
- Culver J, Lowstuter K, Bowling L. Assessing breast cancer risk and BRCA1/2 carrier probability. Breast Dis. 2007;27:5–20. - PubMed
-
- Anczuków O, et al. BRCA2 deep intronic mutation causing activation of a cryptic exon: opening toward a new preventive therapeutic strategy. Clin. Cancer Res. 2012;18(18):4903–4909. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous